Avanti Therapeutics started with a vision that still drives us today: to extend the limits of personalized medicine.  We believe that by applying the methods of leading science to the art of drug development & delivery, we will develop novel therapeutics that will fundamentally change the practice of medicine.

With an innovative, integrated science and technology platform, expertise in drug-target discovery, and industry-leading partnerships, Avanti Therapeutics is geared to prime the product pipeline.

But AT-GC leadership has also recognized that discovering new drug targets is only one step in the pathway toward the ultimate goal of providing novel therapeutic products that would help patient-friendly disease management.  Through the technology commercialization strategy, AT-GC has licensed gene based prophylactic and therapeutic products for infectious diseases and cancer. Today, AT-GC has comprehensive product pipeline, proven commercial capabilities, and more than five product candidates in varying stages of development.  We are continually evolving to ensure that our research and development efforts stay current with the demand for new diagnostic and therapeutic products that will make a genuine difference in patient's lives.

For the rest of the story check out our timeline.